TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jan 19, 2023 10:35 JST
Source:
Eisai
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.
Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Lecanemab Receives Priority Review Status in Japan
January 30 2023 11:50 JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
January 27 2023 10:46 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
January 19 2023 08:07 JST
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
January 18 2023 12:28 JST
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
January 16 2023 17:56 JST
Eisai Launches Renewed Sustainability Page
January 13 2023 14:06 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
January 11 2023 11:52 JST
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09 2023 20:55 JST
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09 2023 19:40 JST
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22 2022 17:07 JST
More Press release >>
Latest Press Release
Honda: Production, Sales and Export Results for December, 2022
Jan 31, 2023 11:57 JST
Mazda Production and Sales Results for December 2022 and for January through December 2022
Jan 31, 2023 11:08 JST
DOCOMO Conducts World's First Trial of Transmissive Metasurface on Window to Deliver Indoor Radio Waves to Outdoor Foot of Building
Jan 30, 2023 17:00 JST
Small, Efficient 5G Multisector Antenna Indoor Base Station Achieves World's First Demonstration using 28GHz
Jan 30, 2023 16:35 JST
DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves
Jan 30, 2023 16:13 JST
NEC announces plans for transition to a Company with a Nominating Committee, etc. and implementation of organizational reforms
Jan 30, 2023 15:44 JST
NEC announces executive personnel changes
Jan 30, 2023 15:28 JST
Toyota: Sales, Production, and Export Results for 2022 (January - December)
Jan 30, 2023 13:36 JST
Lecanemab Receives Priority Review Status in Japan
Jan 30, 2023 12:50 JST
Two Hitachi Group Companies to Merge to Expand Robotic SI Business in Japan and ASEAN Countries
Jan 30, 2023 11:08 JST
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 11:46 JST
TMC Announces Changes to Executive Structure
Jan 27, 2023 10:59 JST
Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region
Jan 26, 2023 19:16 JST
Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact"
Jan 26, 2023 19:02 JST
Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation
Jan 26, 2023 18:28 JST
Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan's Chang Chun Petrochemical
Jan 26, 2023 18:22 JST
Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services
Jan 26, 2023 13:44 JST
All-New eK X EV Earns Top Rating in Vehicle Safety Performance 2022 Car Assessment by JNCAP
Jan 26, 2023 09:01 JST
DOCOMO Announces World's First Technology that Utilizes Human-Augmentation Platform for Sharing Haptic Information Between People
Jan 25, 2023 17:17 JST
More Latest Release >>